However, a composite biomarker profile consisting of KRAS/NRAS/BRAF/PIK3CA mutations was predictive of resistance to anti-EGFR therapy.268 In addition, the BEACON CRC study has established encorafenib combined with cetuximab as a new standard of care for previously treated BRAF V600E-mutant mCRC. This evidence concerns the gene KRAS and colorectal carcinoma.